Business Wire: Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Business Wire: Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Seeking Alpha: Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
A wave of new research and alternative therapies is reshaping how social anxiety is understood and treated, moving beyond traditional clinical models. Studies highlight that fixed mindsets about ...
My client Kay had three diagnoses and a year-long treatment plan. Targeting her personality traits gave us one shorter, more effective approach for all of them.
NDTV on MSN: Social anxiety disorder: Here are some practical tips to keep yourself calm
Social anxiety disorder affects millions of people across the world. The symptoms of SAD usually start in childhood or adolescence and continue into adulthood if untreated.
Social anxiety disorder: Here are some practical tips to keep yourself calm
Forbes: Neuro-Symbolic AI Steps Up To Produce Robust Mental Health Treatment Plans
CBS News: As more Americans embrace anxiety treatment, RFK Jr. derides medications
Positive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety Disorder Company confirms ...